Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants From Rsv Disease During Their First Rsv Season
默沙東宣佈FDA接受Clesrovimab的生物製品許可申請,這是一種旨在保護嬰兒在首個RSV季節中免受RSV疾病影響的實驗性開多單克隆抗體。